Karen Knudsen: Accelerating the development and deployment of innovative radioligand therapies for cancer
Karen Knudsen, Executive Strategic Advisor and Immediate Past CEO of the American Cancer Society (ACS), shared on LinkedIn:
“2025 is shaping up to be a landmark year for Women making exciting career moves! It was so wonderful to catch up with my friend, colleague, and powerhouse, Dr. Margaret Yu, at JPM25, who just joined ARTBIO as Chief Medical Officer.
I’m enthusiastic about what this will mean for accelerating the development and deployment of innovative radioligand therapies for cancer. We’ve already seen incredible advances in this space, but we are only at the cusp of what’s possible for the next generation of radiotherapies! Looking forward to what the rest of 2025 brings.”
Karen E. Knudsen is the Executive Strategic Advisor and Immediate Past CEO of the American Cancer Society (ACS). Prior to joining ACS, Dr. Knudsen served as executive vice president of Oncology Services and enterprise director for Sidney Kimmel Cancer Center at Jefferson Health. She also served as president for the Association of American Cancer Institutes (AACI) and on the board of directors of the American Association for Cancer Research (AACR).
She serves on the board of advisors for the National Cancer Institute, on 12 external advisory boards for NCI-designated cancer centers and on Exai Bio. She is an active member of several committees with the American Society for Clinical Oncology (ASCO), in addition to serving on other academic and for-profit advisory boards.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023